BCI
QNCX icon

Brinker Capital Investments’s Quince Therapeutics QNCX Stock Holding History

Brinker Capital Investments’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-51
Closed -$7.6K – 1834
2024
Q2 		$7.6K Hold
51
– – ﹤0.01% 1710
2024
Q1 		$10.7K Hold
51
– – ﹤0.01% 1681
2023
Q4 		$11.4K Hold
51
– – ﹤0.01% 1646
2023
Q3 		$11.4K Hold
51
– – ﹤0.01% 1607
2023
Q2 		$15.3K Hold
51
– – ﹤0.01% 1617
2023
Q1 		$15.8K Sell
51
-3
-6% -$587 ﹤0.01% 1551
2022
Q4 		$6.84K Buy
+54
New +$9.03K ﹤0.01% 1346

Other funds holding QNCX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Brinker Capital Investments's QNCX Position: Q3 2024 in Review

Brinker Capital Investments sold out of Quince Therapeutics (QNCX) in Q3 2024, closing a stake of 51 shares — an estimated $7.6K sold.

Brinker Capital Investments first reported a position in QNCX in Q4 2022 and held it in 7 quarters. The position peaked at $15.8K in Q1 2023. 32 funds tracked by Wall St. Rank hold QNCX as of Q3 2024.

  • Brinker Capital Investments reported no remaining Quince Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Brinker Capital Investments sold 51 Quince Therapeutics shares in Q3 2024, an estimated $7.6K.
  • Brinker Capital Investments first reported a position in Quince Therapeutics in Q4 2022 and held it in 7 quarters.
  • Brinker Capital Investments's Quince Therapeutics position peaked at $15.8K in Q1 2023.
  • 32 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2024.

Based on Brinker Capital Investments's 13F filing for Q3 2024, filed 31 Jul 2025.